Capital Rx Stock

cap-rx.comHealthcare / Healthcare providers & servicesFounded: 2017Funding to Date: $362.38MM

Capital Rx is a health technology company built around the mission of changing the way prescription drugs are priced and patients are serviced. Its Clearinghouse Model® is the first ethical framework for drug pricing. Capital Rx's enterprise pharmacy platform, JUDI®, connects every aspect of the pharmacy ecosystem in one platform. This company was founded in 2017 and is headquartered in New York, NY.

Register To Buy and Sell Shares

For more details on financing and valuation for Capital Rx, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Capital Rx’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Capital Rx.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Anthony Loiacono
Co-Founder, Chief Executive Officer & Board Member
Ari Fischel
Chief Financial Officer
Joseph Alexander
Co-Founder, Chief Operating Officer, Chief Strategy Officer & Board Member
Ryan Kelly
Co-Founder, Chief Technology Officer & Board Member
Lloyd Fiorini JD
Chief Compliance Officer and General Counsel

Board Members

Jared Kesselheim MD
Transformation Capital
Lenard Marcus
Edison Partners
Robert Mittendorff MD
Board Member
Kevin Hill
Board Member

Frequently Asked Questions About Capital Rx’s Stock

plusminus
Can you buy Capital Rx’s stock?
Capital Rx is not publicly traded on NYSE or NASDAQ in the U.S. To buy Capital Rx’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell Capital Rx’s stock?
Yes, you can sell stock of a private company like Capital Rx. Forge can help you sell your Capital Rx stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is Capital Rx’s stock price?
Capital Rx is a privately held company and therefore does not have a public stock price. However, you may access Capital Rx’s private market stock price with Forge Data.
plusminus
What is Capital Rx’s stock ticker symbol?
Capital Rx does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Capital Rx nabs $50M backed by Inova, Ochsner and other health system investors
Ten health systems, including Banner Health and Memorial Herman, and digital health equity company Transformation Capital, have invested over $50 million in Capital Rx. This investment will support Capital Rx's cloud-native pharmacy benefits administrator and backend claims processing platform JUDI. The funds will be used for research and development, growth of member and client service teams, and key hiring areas within the company.
Capital Rx Closes on $50 Million from Transformation Capital and Others
New York-based Capital Rx, a pharmacy benefit manager and administrator, has secured over $50 million in a funding round led by Transformation Capital. Other participants included Inova Health System, Atlantic Health System, Banner Health, among others. The funds will be used to lower pharmacy costs, improve patient access, and deliver better outcomes. The firm's total funding now stands at $253 million.
Capital Rx CEO: PBM industry needs to be repaired, not ditched
The CEO of start-up Capital Rx, A.J. Loiacono, argues that the Pharmacy Benefit Managers (PBM) industry needs reform, not elimination. While acknowledging the issues with drug pricing, Loiacono maintains that PBMs perform crucial administrative functions in claims administration and patient management among others. Capital Rx recently became the first PBM serving Medicare, Medicaid, and employer-sponsored health plans to earn a B Corp Certification for social responsibility.
Updated on: May 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.